Rustin GJ - Search Results

1

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup. Rustin GJ, et al. Int J Gynecol Cancer. 2011 Feb;21(2):419-23. doi: 10.1097/IGC.0b013e3182070f17. Int J Gynecol Cancer. 2011. PMID: 21270624

2

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Rustin GJ, et al. Ann Oncol. 1996 Apr;7(4):361-4. doi: 10.1093/oxfordjournals.annonc.a010602. Ann Oncol. 1996. PMID: 8805927 Free article.

3

The clinical value of tumour markers in the management of ovarian cancer.

Rustin GJ. Rustin GJ. Ann Clin Biochem. 1996 Jul;33 ( Pt 4):284-9. doi: 10.1177/000456329603300403. Ann Clin Biochem. 1996. PMID: 8836386 No abstract available.

4

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.

Rustin GJ, Quinnell TG, Johnson J, Clarke H, Nelstrop AE, Bollag W. Rustin GJ, et al. Br J Cancer. 1996 Nov;74(9):1479-81. doi: 10.1038/bjc.1996.568. Br J Cancer. 1996. PMID: 8912548 Free PMC article. Clinical Trial.

5

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, Johnson J, Evans H, Brown S, Oster W. Rustin GJ, et al. J Clin Oncol. 1997 Jan;15(1):172-6. doi: 10.1200/JCO.1997.15.1.172. J Clin Oncol. 1997. PMID: 8996139 Clinical Trial.

6

Surveillance policy for stage I ovarian germ cell tumors.

Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ. Dark GG, et al. Among authors: rustin gj. J Clin Oncol. 1997 Feb;15(2):620-4. doi: 10.1200/JCO.1997.15.2.620. J Clin Oncol. 1997. PMID: 9053485

7

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Bridgewater JA, et al. Among authors: rustin gj. J Clin Oncol. 1999 Feb;17(2):501-8. doi: 10.1200/JCO.1999.17.2.501. J Clin Oncol. 1999. PMID: 10080591

8

Use of tumour markers in monitoring the course of ovarian cancer.

Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Rustin GJ, et al. Ann Oncol. 1999;10 Suppl 1:21-7. doi: 10.1023/a:1008351216605. Ann Oncol. 1999. PMID: 10219449

9

Advanced epithelial ovarian cancer: 1998 consensus statements.

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al. Berek JS, et al. Among authors: rustin gj. Ann Oncol. 1999;10 Suppl 1:87-92. doi: 10.1023/a:1008323922057. Ann Oncol. 1999. PMID: 10219460

10

Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.

Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Rustin GJ, et al. J Clin Oncol. 2000 Apr;18(8):1733-9. doi: 10.1200/JCO.2000.18.8.1733. J Clin Oncol. 2000. PMID: 10764434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page